CooperCompanies stock (US21664P1039): Q2 2026 earnings beat and strong price move on Nasdaq

CooperCompanies shares moved sharply higher on Nasdaq after the U.S. medical device group reported Q2 2026 results that topped earnings and revenue expectations, keeping investors focused on the company’s contact lens and women’s health businesses.

CooperCompanies shares advanced notably on the Nasdaq on 06/05/2026 after the California-based medical device group reported quarterly results that exceeded Wall Street expectations, highlighting ongoing momentum in its contact lens and women’s health product lines, according to Zacks on 06/05/2026 and GuruFocus on 06/05/2026.

The CooperCompanies stock, which trades under the ticker COO on the Nasdaq in the United States, gained around 7.5% to about USD 66.70 on 06/05/2026, representing an intraday increase of roughly USD 4.68 compared with the prior close, according to GuruFocus as of 06/05/2026.

As of: 05.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: CooperCompanies
• Sector/industry: Medical devices, vision care and women’s health
• Headquarters/country: San Ramon, United States
• Core markets: North America, Europe, Asia-Pacific
• Key revenue drivers: Contact lenses and fertility/women’s health products
• Home exchange/listing venue: Nasdaq (COO)
• Trading currency: USD

CooperCompanies: core business model

CooperCompanies focuses on specialty contact lenses through its CooperVision unit and women’s health and fertility offerings via its CooperSurgical division, with sales largely driven by recurring demand from eye care professionals and reproductive health clinics.

Valuation metrics and multiples for CooperCompanies

Following the post-earnings move on 06/05/2026, investors are not only looking at the absolute share price but also at how CooperCompanies is valued relative to its recent earnings power, especially after reporting stronger-than-expected profit for Q2 2026, according to Zacks on 06/05/2026.

Zacks reported on 06/05/2026 that for the quarter ended April 2026, CooperCompanies delivered an earnings surprise of 9.67% and a revenue surprise of 2.57% versus consensus estimates, which provides fresh input for commonly watched valuation ratios such as price-earnings and enterprise-value-to-sales, even though precise multiples were not disclosed in that note.

Conclusion

CooperCompanies’ Q2 2026 earnings and revenue beat, as reported by Zacks on 06/05/2026, coupled with the same-day share price jump on the Nasdaq highlighted by GuruFocus on 06/05/2026, put the U.S. group in the spotlight for investors tracking medical device and vision care names.

Against this backdrop, the company’s valuation metrics and its exposure to recurring demand in contact lenses and women’s health products will likely remain key reference points for market participants when comparing CooperCompanies with other listed healthcare peers in the United States and abroad.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.